Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| NewAmsterdam Pharma Company N.V. | Obicetrapib alone or in combination with ezetimibe | Type 2 diabetes or metabolic syndrome | Phase 3 | Ongoing | Oral | Endocrinology |
| NewAmsterdam Pharma Company N.V. | Obicetrapib plus ezetimibe - (REMBRANDT) | High-risk atherosclerotic cardiovascular disease (ASCVD) | Phase 3 | Ongoing | Oral | Cardiology |
| NewAmsterdam Pharma Company N.V. | Obicetrapib - (PREVAIL) | Cardiovascular disease | Phase 3 | Enrollment Conclusion | Oral | Cardiology |
| NewAmsterdam Pharma Company N.V. | Obicetrapib & ezetimibe - (TANDEM) | Cardiovascular disease | Phase 3 | Trial Completed | Oral | Cardiology |
| NewAmsterdam Pharma Company N.V. | Obicetrapib - (BROOKLYN) | Heterozygous familial hypercholesterolemia (HeFH) | Phase 3 | Data Released | Oral | Cardiology |
| NewAmsterdam Pharma Company N.V. | Obicetrapib - (BROADWAY) | Heterozygous Familial Hypercholesterolemia and/or Established Atherosclerotic Cardiovascular Disease | Phase 3 | Data Released | Oral | Cardiology |
| NewAmsterdam Pharma Company N.V. | Obicetrapib w/ Lp(a) - (VINCENT) | Mild dyslipidemia | Phase 2 | Ongoing | Oral | Cardiology |
| NewAmsterdam Pharma Company N.V. | Obicetrapib with Ezetimibe - (ROSE2) | Cardiovascular disease | Phase 2 | Ongoing | Oral | Cardiology |
